Wedbush analyst Liana Moussatos reiterated her Outperform rating and $224 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after protocol amendments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE